glp-1 drug coverage How Employers Can Manage Costs in Their Health Plans GLP-1s and The Payer Predicament

This formulation may not include additional additives but comes with the regulatory assurance of 503b compliance

Safety & Contraindications Regulatory reality first: Retatrutide is investigational and not approved by the FDA or EMA for any indication

Update: The FDA has issued a Complete Response Letter (CRL) to bardoxolone methyl, which indicates that the FDA cannot approve the NDA in its present form

This article is exclusive to STAT+ subscribers Unlock this article plus daily intelligence on Capitol Hill and the life sciences industry by subscribing to STAT+

When used incorrectly, they are just expensive noise layered on top of dysfunction

These signals suppress appetite, slow gastric emptying, enhance insulin secretion, and promote satiety